AML1ETO AML – M2 Test
Test Name: AML1ETO AML – M2 Test
Components: Sodium Heparin Vacutainer (2ml)
Price: 1050.0 AED
Sample Condition: Bone Marrow / Peripheral blood
Report Delivery: 3-4 days
Method: FISH
Test type: Genetics
Doctor: Oncology
Test Department:
Pre Test Information: AML1/ETO (AML – M2) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
AML1/ETO, also known as RUNX1/RUNX1T1, is a specific genetic abnormality that is found in a subtype of acute myeloid leukemia (AML) known as AML-M2. AML-M2 is characterized by the presence of abnormal myeloblasts (immature white blood cells) in the bone marrow.
The AML1/ETO fusion gene is formed as a result of a chromosomal translocation between the AML1 (also known as RUNX1) gene on chromosome 21 and the ETO (also known as RUNX1T1) gene on chromosome 8. This translocation leads to the fusion of the two genes, resulting in a chimeric protein known as AML1/ETO.
The AML1/ETO fusion protein interferes with normal blood cell development by disrupting the normal function of the AML1 gene. The AML1 gene is responsible for regulating the differentiation and maturation of blood cells. When the AML1/ETO fusion protein is present, it disrupts this process and promotes the accumulation of immature myeloblasts in the bone marrow, leading to the development of AML-M2.
Patients with AML-M2 with the AML1/ETO fusion gene often have a poorer prognosis compared to other subtypes of AML. However, with advancements in targeted therapies and stem cell transplantation, the prognosis for AML-M2 patients has improved in recent years.
Test Name | AML1ETO AML – M2 Test |
---|---|
Components | Sodium Heparin Vacutainer (2ml) |
Price | 1050.0 AED |
Sample Condition | Bone Marrow \/ Peripheral blood |
Report Delivery | 3-4 days |
Method | FISH |
Test type | Genetics |
Doctor | Oncology |
Test Department: | |
Pre Test Information | AML1/ETO (AML – M2) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
Test Details |
AML1/ETO, also known as RUNX1/RUNX1T1, is a specific genetic abnormality that is found in a subtype of acute myeloid leukemia (AML) known as AML-M2. AML-M2 is characterized by the presence of abnormal myeloblasts (immature white blood cells) in the bone marrow. The AML1/ETO fusion gene is formed as a result of a chromosomal translocation between the AML1 (also known as RUNX1) gene on chromosome 21 and the ETO (also known as RUNX1T1) gene on chromosome 8. This translocation leads to the fusion of the two genes, resulting in a chimeric protein known as AML1/ETO. The AML1/ETO fusion protein interferes with normal blood cell development by disrupting the normal function of the AML1 gene. The AML1 gene is responsible for regulating the differentiation and maturation of blood cells. When the AML1/ETO fusion protein is present, it disrupts this process and promotes the accumulation of immature myeloblasts in the bone marrow, leading to the development of AML-M2. Patients with AML-M2 with the AML1/ETO fusion gene often have a poorer prognosis compared to other subtypes of AML. However, with advancements in targeted therapies and stem cell transplantation, the prognosis for AML-M2 patients has improved in recent years. |